Fetching results...
0 items found

A0540: Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort

D. Raggi, Milan (IT)
Necchi A.1, Basile G.2, Bandini M.2, Raggi D.1, Marandino L.1, Costa De Padua T.1, Patanè D.1, Crupi E.1, Del Prete A.3, Colombo R.2, Colecchia M.4, Luciano R.4, Moschini M.2, Ross J.5, Gibb E.6, Briganti A.2, Montorsi F.2, De Cobelli F.3, Brembilla G.3
1IRCCS Ospedale San Raffaele, Dept. of Medical Oncology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, 4IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy, 5Foundation Medicine, Medical Director, Cambridge, United States of America, 6Veracyte Inc., Vancouver, Canada
38th Annual EAU Congress
Date – Time - Location
12 March 2023, 10:45 - 12:15, Pink Area, Coral 3
Abstract Session 26 - Metastatic urothelial cancer: News in immunotherapy and more
Urothelial Cancer, MIBC - Treatment, Imaging
  • © 2023 European Association of Urology
  • Disclaimer